Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro

LEVERKUSEN, Germany Wed Nov 14, 2012 3:17pm IST

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011. REUTERS/Fabrizio Bensch

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011.

Credit: Reuters/Fabrizio Bensch

Related Topics

Stocks

   

LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).

The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.

Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.

(Reporting by Frank Siebelt; Writing by Ludwig Burger)

FILED UNDER:

Health

REUTERS SHOWCASE

Space Programme

Space Programme

ISRO tests its heaviest space launch vehicle, eyes global market.  Full Article 

Priya's Shakti

Priya's Shakti

Rape survivor turns "superhero" in India's first digital comic.  Full Article 

U.S.-Cuba Ties

U.S.-Cuba Ties

U.S., Cuba restore ties after 50 years.  Full Article 

Threat Works

Threat Works

Sony cancels N.Korea movie in apparent win for Pyongyang hackers.  Full Article 

A Minute With

A Minute With

Reuters interviews Rajkumar Hirani ahead of the release of "PK".  Full Article 

Safety Concerns

Safety Concerns

Uber plans tighter screening for drivers.  Full Article 

New Tax Regime

New Tax Regime

Cabinet clears bill for nationwide goods and services tax.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device   Full Coverage